title: Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro.
abstract: OBJECTIVE
  Oxidative injury in schizophrenia may be caused not only by pathophysiological processes but partly also by treatment with antipsychotics. The purpose of the present study was to examine and to compare the effects of quetiapine (QUE), olanzapine (OLA) and haloperidol (HAL), at final concentrations corresponding to doses used for treatment of acute episodes of schizophrenia, on plasma lipid peroxidation in vitro, measured by the level of thiobarbituric acid-reactive substances (TBARS).
  
  
  METHODS
  Blood from 30 healthy volunteers was collected into ACD (citric acid/citrate/dextrose) solution. The drugs in form of active substances were dissolved in 0.01% dimethyl sulfoxide, added to plasma at the final concentrations [QUE (175 and 275 ng/ml), OLA (20 and 40 ng/ml), HAL (4 and 20 ng/ml)] and incubated for 1 and 24 h at 37 °C. The level of TBARS was measured spectrophotometrically (according to the Rice-Evans method, 1991).
  
  
  RESULTS
  The comparative study in vitro showed that QUE causes a decrease in the TBARS level in plasma, whereas HAL increases the plasma TBARS level. After 24 h of incubation of plasma with QUE or HAL (at lower and higher concentrations),thedifferences in TBARS levels between the drugs were significant (p = 5.9 × 10⁻⁴, p = 2.2 × 10⁻⁵, respectively).
  
  
  CONCLUSIONS
  QUE and OLA, contrary to the prooxidative action of HAL, did not induce oxidative stress; moreover, QUE has antioxidant properties.
authors.affiliation: Department of Affective and Psychotic Disorders, Medical University of Lodz, Lodz, Poland. tzn_lodz @ post.pl
authors.forename: Anna
authors.initials: A
authors.lastname: Dietrich-Muszalska
authors.forename: Bogdan
authors.initials: B
authors.lastname: Kontek
authors.forename: Jolanta
authors.initials: J
authors.lastname: Rabe-Jabłońska
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology*; D003987:Dibenzothiazepines / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D000077152:Olanzapine; D010949:Plasma / Q000378:metabolism; D000069348:Quetiapine Fumarate; D013053:Spectrophotometry / Q000379:methods; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D017392:Thiobarbituric Acid Reactive Substances; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D006220:Haloperidol; D000077152:Olanzapine